

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal


Darolutamide with androgen deprivation therapy for treating hormonesensitive metastatic prostate cancer ID6452

Provisional Stakeholder List


Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
Bayer (darolutamide)	All Wales Therapeutics and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
Black Health Agency for Equality Bob Champion Cancer Trust	Board of Community Health Councils in Wales
Cancer Black Care	British National Formulary
	•
Cancer Equality Halon Ballacon Concer Charity	Can't Caramy Commission
Helen Rollason Cancer Charity Independent Cancer Definite Value Value	Department of Health - Northern Ireland Lighthaum Ireland
Independent Cancer Patients Voice Magnetiller Cancer Patients Voice	Healthcare Improvement Scotland Madicines and Use Illustrations
Macmillan Cancer Support	Medicines and Healthcare products
Maggie's Centres	Regulatory Agency
Marie Curie	National Association of Primary Care
Orchid	National Pharmacy Association
PCaSO - Prostate Cancer Support	NHS Confederation
Organisation	Scottish Medicines Consortium
Pelican Cancer Foundation	Welsh Government
Prost8 UK	Welsh Health Specialised Services
Prostate Cancer Research	Committee
Prostate Cancer UK	
Prostate Matters UK	Possible comparator companies
South Asian Health Foundation	Accord (bicalutamide, docetaxel,
Specialised Healthcare Alliance	relugolix)
Tackle Prostate Cancer Tenovus Cancer Care	 Amdipharm Mercury Company (flutamide)
	Astellas Pharma (enzalutamide)
Healthcare professional groups	AstraZeneca (bicalutamide, goserelin)
Association of Anaesthetists	Bayer (cyproterone acetate)
Association of Cancer Physicians	Ferring Pharmaceuticals (degarelix,
Association of Surgeons of Great	triptorelin)
Britain and Ireland	Hospira UK (docetaxel)
British Association of Urological	Ipsen (triptorelin)
Nurses	Kent Pharma (cyproterone acetate)
British Geriatrics Society	Mylan (flutamide)
British Institute of Radiology	Neon Healthcare (buserelin)
2.mon monate of radiology	Seacross (docetaxel)

Provisional stakeholder list for the evaluation of darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer ID6452 Issue date: November 2024





Provisional Consultees Provisional Commentators (no right to submit or appeal) Sun Pharma (bicalutamide) **British Oncology Pharmacy** Association Takeda (leuprorelin) British Psychosocial Oncology Society Typharm (leuprorelin) British Uro-Oncology Group Cancer Research UK Relevant research groups Prostate Cancer Advisory group Cochrane Urology Royal College of Anaesthetists Genomics England Institute of Cancer Research Royal College of General Practitioners Royal College of Nursing MRC Clinical Trials Unit Royal College of Pathologists Pro Cancer Research Fund Royal College of Physicians Associated Public Health groups Royal College of Radiologists Public Health Wales Royal College of Surgeons UK Health Security Agency Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers **UK Clinical Pharmacy Association UK Oncology Nursing Society Urology Foundation Others** Department of Health and Social Care NHS England



NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

arolutamide with androgen deprivation therapy for treating hormonesensitive metastatic prostate cancer ID6452

Provisional Stakeholder List

ovisional Consultees	Provisional Commentators (no right submit or appeal)
mpany	General
Bayer (darolutamide)	All Wales Therapeutics and Toxic Centre
tient/carer groups	Allied Health Professionals Federa
Black Health Agency for Equality	Board of Community Health Coun
Bob Champion Cancer Trust	Wales
Cancer Black Care	British National Formulary
Cancer Equality	Care Quality Commission
Helen Rollason Cancer Charity	Department of Health - Northern I
Independent Cancer Patients Voice	Healthcare Improvement Scotlanc
Macmillan Cancer Support	Medicines and Healthcare produc
Maggie's Centres	Regulatory Agency
Marie Curie	National Association of Primary C
Orchid	 National Pharmacy Association
PCaSO - Prostate Cancer Support	NHS Confederation
Organisation	Scottish Medicines Consortium
Pelican Cancer Foundation	Welsh Government
Prost8 UK	Welsh Health Specialised Service
Prostate Cancer Research	Committee
Prostate Cancer UK	
Prostate Matters UK	Possible comparator companies
South Asian Health Foundation	Accord (bicalutamide, docetaxel,
Specialised Healthcare Alliance	relugolix)
Tackle Prostate Cancer	Amdipharm Mercury Company (fluta maids.)
Tenovus Cancer Care	(flutamide)
	Astellas Pharma (enzalutamide) Astro-Zamana (hipalutamida magan
althcare professional groups	AstraZeneca (bicalutamide, goser Payer (symptotrope apoteta)
Association of Anaesthetists	Bayer (cyproterone acetate) - Foreign Pharmacouticals (degradiants)
Association of Cancer Physicians	Ferring Pharmaceuticals (degareling)
Association of Surgeons of Great	triptorelin)Hospira UK (docetaxel)
British Association of Uralagical	Hospira UK (docetaxel)Ipsen (triptorelin)
British Association of Urological	Kent Pharma (cyproterone acetate)
Nurses Pritish Corietries Society	 Mylan (flutamide)
British Destitute of Rediclory	Neon Healthcare (buserelin)
British Institute of Radiology	Seacross (docetaxel)
-	■ Seacioss (docetaxei)

Provisional stakeholder list for the evaluation of darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer ID6452 Issue date: November 2024



NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.